Product name

Diagnostic assay for the identification of non-M3 AML Patients suitable for an all-trans retinoic acid therapy

Summary

In-licensing opportunity for a diagnostic test based on patient blood samples.

Organization name

Ascenion GmbH

Profile

Presently, acute myeloid leukemia (AML) patients being diagnosed with the M3 subtype are treated with all-trans retinoic acid (ATRA) with a good success rate. However, in a significant fraction of non-M3 patients, administration of ATRA only leads to the severe side effects of this treatment, without significantly improving the health status of the patients.

To-date, no predictive marker is known that can be correlated with a therapeutic effect of ATRA in the treatment of AML not being classified as M3 subtype. As a consequence, identification of the small fraction of non-M3 patients that would benefit of ATRA remains unattainable, and admittance to this powerful treatment mostly is denied.  

The Technology

A newly developed assay allows for the selection of non-M3 AML patients suitable for an all-trans retinoic acid therapy. The determination of the relevant group is facilitated by an fast and easy diagnostic test for a certain level of MN1 as a specific marker.

A transcription level assay has been successfully evaluated in a group of patients diagnosed with non-M3 AML. Significantly higher event-free survival rate of selected patients after ATRA treatment proves the correlation of marker level and therapeutic effect.  

An US patent application has been filed in 2007.  

Contact

Dr. Ralf Cordes
cordes(at)ascenion.de

About Ascenion

Ascenion is the exclusive partner of 12 life-science institutes in the Helmholtz and Leibniz Associations and of one Medical School, and coordinates technology transfer for the German National Genome Research Network. They currently market around 600 technologies, together with a varied range of research materials, e.g. antibodies, animal models and vectors.    

Description File

 TO_15-00005_ATRA.pdf

Your feedback

back

Search

Sector

--- select from list ---AgroBiotechnologyBiomedicine, DiagnosticsCosmeticsEnabling Technology, Platform TechnologyEnvironmentalFine ChemicalsFoodMedical DeviceProduction, Development ServicesVeterinary

Technology

--- select from list ---AnalyticalAnimal ModelAntibody BasedAntisense, NucleotideBioinformaticBiologicalBlood Products, SubstitutesBreeding, CultivationChemistryClinical Research ServicesCompound LibrariesDiagnostic Assay, KitDrug DeliveryDrug DiscoveryDrugs, Small MoleculeEngineeringEnzymesGene Therapy, VectorsGenomicsHigh Throughput ScreeningImagingImplantIndustrial Waste Treatment, RemediationNanotechnologyNatural ProductsPeptides, ProteinsPharmacogenomicsPreclinical Research ServiceProteomicsReagents, Media RegenerationRenewable resourcesSurgical InstrumentationTissue Engineering, BiomaterialTransgenic OrganismTransplantVaccines

Development Stage

--- select from list ---Clinical Phase IClinical Phase IIClinical Phase IIIClinical Phase IV/MarketedIdea, Conceptin-vitro TestingLead Compound/SeriesPreclinicalProof-of-principlePrototypeRepurposingTarget Identification, Validation, Drug Discovery

Disease Category

--- select from list ---(Auto) ImmuneCancerous, neoplasmaticInfectious, ParasiticInflammatoryInherited, NeonatalMetabolic, EndocrineOther, organ-specific diseases

Organ

--- select from list ---BloodBoneBrainBreastCardiovascularCartilageCNS, Nerves, SpineEarEsophagusEyeGynecologyHeartImmune SystemIntestineLiverMusclePancreasPNSProstate and male sexual healthPsychiatry, psychologyRespiratorySkinTeethUrology, kidney